Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
The invention relates to pharmaceutical combinations of potassium channel openers and sodium channel inhibitors for treating pains which are accompanied by an increase in muscle tone.
1 ) The use of potassium channel openers in combination with sodium channel-inhibiting or -influencing substances, or of their therapeutically utilizable salts, for treating pains which are accompanied by an increase in muscle tone.
2 ) The use as claimed in claim 1 , wherein the potassium channel openers employed are flupirtine or its pharmaceutically utilizable salts.
3 ) The use as claimed in claim 1 , wherein the sodium channel-inhibiting or -influencing substances employed are tolperisone or its analogs eperisone or silperisone, or riluzole, propafenone, lidocaine, flecainide or metixen, or their pharmaceutically utilizable salts.
4 ) The use as claimed in claim 1 , wherein the sodium channel-inhibiting or -influencing substances employed are tolperisone or its analogs, such as eperisone or silperisone, or their pharmaceutically utilizable salts.
5 ) The use of flupirtine in combination with tolperisone or its analogs, such as eperisone or silperisone, or their pharmaceutically utilizable salts, for treating pains which are accompanied by an increase in muscle tone.
6 ) The use as claimed in claim 1 , for treating pains associated with neuralgias.
7 ) The use as claimed in claim 1 , for treating pains associated with arthritis and arthrosis.
8 ) The use as claimed in claim 1 , for treating pains associated with chronic or episodic tension headache.
9 ) The use as claimed in claim 1 , for treating pains associated with lower spastic paraparesis syndrome (e.g. lower paraspasm, transverse myelitis, multiple sclerosis, heritable inferior spastic paraplegia (Stuempel paraplegia), disturbances of the spinal blood circulation and cerebral paralysis involving lower spastic paresis).
10 ) The use as claimed in claim 1 , for treating pains associated with tetraparesis in connection with cervical myelopathy, cervical brachialgia or vertebral dysplasia.
11 ) The use as claimed in claim 1 , for treating pains associated with Parkinson's disease.
12 ) The use of potassium channel openers in combination with sodium channel-inhibiting or -influencing substances, and of their therapeutically utilizable salts, for producing a medicament for oral, rectal, intravenous, transdermal or subcutaneous or intracutaneous administration for treating pains which are accompanied by an increase in muscle tone.